Bladder cancer

Current Opinion in Oncology

Volumn 18, Issue 3, 2006, Pages 277-283

  Gwynn, Eric S ^a   Clark, Peter E ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Bladder cancer; Diagnosis; Review; Treatment

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; ANTINEOPLASTIC AGENT; BCG VACCINE; BIOLOGICAL MARKER; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; HYPERICIN; METHOTREXATE; MITOMYCIN C; NUCLEAR MATRIX PROTEIN 22; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

ADVANCED CANCER; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; CYSTECTOMY; CYSTOSCOPY; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; FLUORESCENCE; HUMAN; OPTIMAL DRUG DOSE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUPERFICIAL CANCER; UNSPECIFIED SIDE EFFECT; URINARY DIVERSION;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE MANAGEMENT; HUMANS; IMMUNOTHERAPY; LYMPH NODE EXCISION; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; URINARY BLADDER NEOPLASMS;

EID: 33646686337     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000219258.75961.1a     Document Type: Review

References (73)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Lerner SP. Bladder cancer clinical trials. Urol Oncol 2005; 23:275-279.
3. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta 2004; 340:57-65.
4. Quek ML, Sanderson K, Daneshmand S, Stein JP. New molecular markers for bladder cancer detection. Curr Opin Urol 2004; 14:259-264.
5. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; 47:736-748.
6. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293:810-816. This was a prospective, predominately community-based trial on the detection of bladder cancer using the NMP-22 urinary marker.
7. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 2005; 294:2052-2056.
8. Sim HG, Lau WK, Olivo M, et al. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma? BJU Int 2005; 95:1215-1218.
9. Babjuk M, Soukup V, Petrik R, et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005; 96:798-802.
10. Jain S, Kockelbergh RC. The role of photodynamic diagnosis in the contemporary management of superficial bladder cancer. BJU Int 2005; 96:17-21. This is a review describing the potential improvement in cystoscopic detection of bladder cancer by the use of PDD.
11. Zaak D, Karl A, Knuchel R, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 2005; 96:217-222.
12. Shariat SF, Zippe C, Ludecke G, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005; 173:1518-1525. Evaluation of a nomogram incorporating NMP-22 to help predict recurrence and progression in superficial bladder cancer.
13. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005; 11:4029-4036.
14. Blaveri E, Brewer JL, Roydasgupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005; 11:7012-7022.
15. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005; 11:4044-4055.
16. Memon AA, Chang JW, Oh BR, Yoo YJ. Identification of differentially expressed proteins during human urinary bladder cancer progression. Cancer Detect Prev 2005; 29:249-255.
17. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005; 23:2903-2910.
18. Gu J, Zhao H, Dinney CP, et al. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res 2005; 11:1408-1415.
19. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate post-operative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171:2186-2190, quiz 2435.
20. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90-95.
21. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004; 93:485-490.
22. Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970.
23. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63:682-686; discussion 686-687.
24. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174:86-91; discussion 91-92. This meta-analysis showed the superiority of BCG over chemotherapy for the treatment of CIS.
25. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163:1124-1129.
26. Lamm DL Preventing progression and improving survival with BCG maintenance. Eur Urol 2000; 37 (Suppl 1):9-15.
27. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174:1242-1247. This prospective randomized trial demonstrated that a dose reduction in BCG can significantly reduce toxicity without compromising efficacy of treatment.
28. Moskovitz B, Meyer G, Kravtzov A, et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005; 16:585-589.
29. van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004; 46:65-71; discussion 71-72.
30. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003; 170:777-782.
31. Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology 2005; 65:65-69.
32. Mattioli F, Curotto A, Manfredi V, et al. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer Res 2005; 25:2493-2496.
33. Campodonico F, Canepa G, Capponi G, et al. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res 2005; 25:2381-2384.
34. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002; 20:3193-3198.
35. Gontero P, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. BJU Int 2005; 96:970-976.
36. Perabo FG, Muller SC. New agents in intravesical chemotherapy of superficial bladder cancer. Scand J Urol Nephrol 2005; 39:108-116.
37. Joudi FN, O'Donnell MA. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures. Curr Opin Urol 2004; 14:271-275.
38. Prout G, Marshall VF. The prognosis with untreated bladder tumors. Cancer 1956; 9:551-558.
39. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001; 19:666-675.
40. Stein JP, Skinner DG. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol Clin North Am 2005; 32:187-197.
41. Clark PE, Stein JP, Groshen SG, et al. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer 2005; 103:546-552.
42. Clark PE, Stein JP, Groshen SG, et al. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer 2005; 104:36-43.
43. Konety BR, Dhawan V, Allareddy V, Joslyn SA. Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project. J Urol 2005; 173:1695-1700.
44. Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol 2005; 173:1318-1322. This review provides an in depth analysis and evaluation of quality of life and type of urinary diversion.
45. Porter MP, Wei JT, Penson DF. Quality of life issues in bladder cancer patients following cystectomy and urinary diversion. Urol Clin North Am 2005; 32:207-216.
46. Gerharz EW, Mansson A, Hunt S, et al. Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol 2005; 174:1729-1736.
47. Gerharz EW, Mansson A, Mansson W. Quality of life in patients with bladder cancer. Urol Oncol 2005; 23:201-207.
48. Yang S, Huang YH, Ou Yang CM, et al. Clinical experience of laparoscopic-assisted radical cystectomy with continent ileal reservoir. Urol Int 2005; 74:240-245.
49. Simonato A, Gregori A, Lissiani A, et al. Laparoscopic radical cystoprostatectomy: our experience in a consecutive series of 10 patients with a 3 years follow-up. Eur Urol 2005; 47:785-790; discussion 790-782.
50. Cathelineau X, Arroyo C, Rozet F, et al. Laparoscopic assisted radical cystectomy: the Montsouris experience after 84 cases. Eur Urol 2005; 47:780-784. Promising results from a single center experience with laparoscopic assisted radical cystectomy in a relatively large number of patients.
51. Arroyo C, Andrews H, Rozet F, et al. Laparoscopic prostate-sparing radical cystectomy: the Montsouris technique and preliminary results. J Endourol 2005; 19:424-428.
52. Moinzadeh A, Gill IS, Desai M, et al. Laparoscopic radical cystectomy in the female. J Urol 2005; 173:1912-1917.
53. Finelli A, Gill IS, Desai MM, et al. Laparoscopic extended pelvic lymphadenectomy for bladder cancer: technique and initial outcomes. J Urol 2004; 172:1809-1812.
54. Shipley WU, Zietman AL, Kaufman DS, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates: the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 2005; 15:36-41.
55. Rodel C, Weiss C, Sauer R. Organ preservation by combined modality treatment in bladder cancer: the European perspective. Semin Radiat Oncol 2005; 15:28-35.
56. Sumiyoshi Y. Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives. Int J Clin Oncol 2004; 9:484-490.
57. Danesi DT, Arcangeli G, Cruciani E, et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer 2004; 101:2540-2548.
58. Pos F, Horenblas S, Dom P, et al. Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys 2005; 61:678-686.
59. Nieuwenhuijzen JA, Pos F, Moonen LM, et al. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005; 48:239-245.
60. Lodde M, Palermo S, Comploj E, et al. Four years experience in bladder preserving management for muscle invasive bladder cancer. Eur Urol 2005; 47:773-778; discussion 778-779.
61. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003; 4:489-497.
62. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004; 171:561-569.
63. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005; 174:14-20.
64. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11:2625-2636.
65. Sonpavde G, Petrylak DP. Perioperative chemotherapy for bladder cancer. Crit Rev Oncol Hematol 2006; 57:133-144.
66. Pectasides D, Pectasides M, Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol 2005; 48:60-67; discussion 67-68.
67. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608. This randomized phase III trial demonstrated similar long-term overall and progression-free survival after treatment with gemcitabine and cisplatin or MVAC and less toxicity with the gemcitabine and cisplatin regimen.
68. Lehmann J, Retz M, Wiemers C, et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005; 23:4963-4974.
69. Hussain SA, Stocken DD, Riley P, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 2004; 91:844-849.
70. Adamo V, Magno C, Spitaleri G, et al. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology 2005; 69:391-398.
71. Ardavanis A, Tryfonopoulos D, Alexopoulos A, et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005; 92:645-650.
72. Lorusso V, Crucitta E, Silvestris N, et al. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium. Oncol Rep 2005; 13:283-287.
73. Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7:2440-2447.